STOCK TITAN

Karyopharm: RA Capital reports 9.99% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Karyopharm Therapeutics Inc. (KPTI) had four reporting persons each report beneficial ownership of 2,517,362 common shares as of September 30, 2026, representing 9.99% of the class. The reporting persons are RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., and RA Capital managers Peter Kolchinsky and Rajeev Shah. Each reported shared voting and dispositive power over that amount; the Fund delegated those powers to RA Capital, its investment adviser.

The Fund directly holds pre-funded warrants exercisable for up to 3,391,164 shares. The warrant blocker restricts exercise if it would result in ownership above 9.99%; the Fund is currently prohibited from exercising to the extent that reporting persons’ beneficial ownership would exceed 2,517,362 shares. The percentage calculation uses 22,681,460 common shares outstanding as of August 6, 2026, with effect given to warrants exercisable within 60 days. Cover pages show 9.9%, rounded down for EDGAR field limitations.

Beneficial ownership 2,517,362 shares Reported by each reporting person as of September 30, 2026; shared voting and dispositive power.
Ownership percentage 9.99% As of September 30, 2026; the cover pages display 9.9%, rounded down due to EDGAR field limitations.
Pre-funded warrants Up to 3,391,164 shares Held directly by RA Capital Healthcare Fund, L.P.; subject to the Beneficial Ownership Blocker.
Common shares outstanding 22,681,460 shares As of August 6, 2026; used as the stated basis for the ownership percentage calculation, with effect given to warrants exercisable within 60 days.
Pre-Funded Warrants financial
"the Fund directly holds pre-funded warrants"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Beneficial Ownership Blocker technical
"the provision (the “Beneficial Ownership Blocker”)"
A beneficial ownership blocker is a legal or structural device that prevents a shareholder from being treated as the ultimate owner of enough shares to trigger control, reporting, or voting thresholds. Think of it like a speed bump that stops an investor from reaching a stake size that would force corporate disclosure or change control rights. Investors care because it affects who controls the company, how shares vote, regulatory filings, takeover risk and therefore potential value or liquidity of their holdings.
beneficial ownership regulatory
"aggregate number of shares ... beneficially owned"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
investment adviser financial
"RA Capital serves as investment adviser for the Fund"
An investment adviser is a person or firm that professionally manages money and gives recommendations about buying, selling, or holding investments. Like a financial coach or guide, they have a legal duty to act in a client's best financial interest, so their advice, fees and potential conflicts can directly affect returns and risk — making their role important for investors who want informed, accountable help with portfolios.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KPTI shares did the reporting persons report owning?

Each of the four reporting persons listed beneficial ownership of 2,517,362 common shares as of September 30, 2026, or 9.99% of the class. Each reported shared voting and dispositive power over that amount.

What is the KPTI warrant exercise limit?

RA Capital Healthcare Fund, L.P. holds pre-funded warrants exercisable for up to 3,391,164 Karyopharm shares. Exercise is restricted if it would cause the Fund, its affiliates and other attribution parties to own more than 9.99%; the amendment says exercise is currently prohibited to the extent reporting persons’ beneficial ownership would exceed 2,517,362 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





48576U205

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



RA Capital Management, L.P.
Signature:/s/ Peter Kolchinsky
Name/Title:By Peter Kolchinsky, Authorized Signatory
Date:11/16/2026
Peter Kolchinsky
Signature:/s/ Peter Kolchinsky
Name/Title:Peter Kolchinsky
Date:11/16/2026
Rajeev Shah
Signature:/s/ Rajeev Shah
Name/Title:Rajeev Shah
Date:11/16/2026
RA Capital Healthcare Fund, L.P.
Signature:/s/ Peter Kolchinsky
Name/Title:By RA Capital Healthcare Fund GP, LLC, its General Partner, By Peter Kolchinsky, Manager
Date:11/16/2026
Exhibit Information

Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to the Reporting Persons' Schedule 13G filed with the SEC on April 2, 2026)

Keep reading